Despite no change in total tau or Aβ burden, a 27% decrease in insoluble Aβ42/Aβ40 ratio was observed in the hippocampus of old 3xTg-AD mice following CL-316,243 injections. This evidence concerns the gene MAPT and Alzheimer disease.